CBD

Dose/route boundary: a single 25 mg dose of standardized CBD extract was studied as a sublingual wafer in healthy volunteers; this does not establish repeated 1-3-times-daily use or sublingual oil.

For the single-dose study, the design was an open-label, 4-way crossover in 12 healthy volunteers randomised to receive a sequence of 4 different single doses of CBD as a sublingual wafer (25 or 50 mg CBD), oil solution (50 mg CBD), or nabiximols oromucosal spray (20 mg CBD, 21.6 mg tetrahydrocannabinol).

A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. British journal of clinical pharmacology · 2021 · PMID 33075170

Evidence scope. Human phase 1 study in 12 healthy volunteers; single-dose sublingual wafer (25 or 50 mg), 50 mg oil, or nabiximols comparator, plus a separate 50 mg twice-daily wafer phase.

Primary safety at the studied sublingual doses: the extract was generally well tolerated, with mild or moderate somnolence, sedation, and altered mood reported.

The extract was generally well tolerated by participants when administered in either wafer or oil form, with some adverse events, including mild or moderate somnolence, sedation and altered mood.

A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single-dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. British journal of clinical pharmacology · 2021 · PMID 33075170

Evidence scope. Human phase 1 healthy-volunteer study; standardized Cannabis sativa extract, not an unstandardized consumer oil or vape product.